KOL Views: What do new data say about the pursuit of a functional cure for HBV infection?

This year’s edition of The Liver Meeting offered up several readouts for combination regimens that companies hope could emerge as a functional cure for chronic hepatitis B virus (HBV) infection, perhaps none more interesting than a triplet from Arrowhead Pharmaceuticals and Johnson & Johnson in Phase II testing.

To provide FirstWord readers with rapid feedback on the state of HBV drug development, we are hosting an expert call with a key opinion leader (KOL) later this week.

Key topics that will be discussed during the call include, among other things… what were the most important HBV-related takeaways from this year’s meeting; does a functional cure ever looked feasible now than ever before; how impressed were you with the first data from Arrowhead/Johnson & Johnson’s triple combination; does this look like it could be the first functional cure for chronic HBV or is it more likely an important template off of which to build/improve; does the regimen – a core/capsid inhibitor, nucleos(t)ide inhibitor and gene-silencing candidate – look like the strongest combination; what other targets or modalities could be included in a regimen, and are there reasons why they could make more sense; are there any other combinations for which there are particularly compelling data or perhaps even mechanistic rationale; if you were to guess, how many years will it be until an initial 'functional cure' is approved; thinking back on how the hepatitis C virus (HCV) market evolved, is HBV likely to be dominated by the first- and/or best-in-class regimen (perhaps due to the emergence of a sofosbuvir-like trailblazer) or will it be more segmented; and what readouts are you most looking forward to in 2020?

Ask the expert!

Furthermore, we invite FirstWord Pharma readers to submit their own questions for consideration. Please click here to do so. We can't guarantee that all questions submitted will be asked due to time constraints, but we will do our utmost to cover the important issues relating to HBV drug development.

We endeavour to provide feedback from KOLs as quickly as possible. Interview content will be published for FirstWord Pharma PLUS subscribers to read. To be notified when the interview content is available please click here.

To ensure access to all KOL Views content, click here to upgrade your FirstWord Pharma service or contact us to discuss your market intelligence needs.

As always, FirstWord would very much like to receive your feedback and suggestions.

To read more KOL Views articles, click here.